Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?

By Shitij Kapur, A. Phillips, Thomas R. Insel. Molecular Psychiatry, 2012

967 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Genetics, Health, Toxicology and Mutagenesis

View Paper: https://www.semanticscholar.org/paper/1fdf98b2c4729bcca7e55b07f9fe0916ded91acb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. Quentin J. M. Huys
2. Gustavo Deco
3. Morten L. Kringelbach
4. Tiago V. Maia
5. Michael J Frank
6. Gaël Varoquaux

In Genetics

1. Frank Dudbridge
2. Naomi R. Wray
3. Sang Hong Lee
4. Terrie E. Moffitt
5. Richie Poulton
6. Avshalom Caspi
7. A. Vinkhuyzen
8. C. Middeldorp

In Health, Toxicology and Mutagenesis

1. Quentin J. M. Huys
2. Tiago V. Maia
3. Michael J Frank
4. Gaël Varoquaux
5. Carol Worthman
6. J. Belsky
7. Julia Kim-Cohen
8. E. Nestler

Citations in the corpus

• Research review: Polygenic methods and their application to psychiatric traits. (2014, background): “References: Hamshere, Langley, et al. (2013); Martin et al.”
• Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study (2014, neutral): “, 2013), the striking lack of progress in identifying biomarkers associated with depression diagnosis or treatment response (Hek et al., 2013; Kapur et al., 2012; Tansey et al., 2012), and the low efficacy of antidepressants in clinical trials (Kirsch et al.”
• Deriving reproducible biomarkers from multi‐site resting‐state data: An Autism‐based example (2016, background): “However, compared to other fields of medicine, psychiatry lacks accompanying objective markers that could lead to more refined diagnoses and targeted treatment [1].”
• The p Factor: One General Psychopathology Factor in the Structure of Psychiatric Disorders? (2014, background): “Translational studies seeking biomarkers for one disorder certainly should include not only healthy control participants but also psychiatric control participants who have other disorders (Kapur et al., 2012; Schwartz & Susser, 2011).”
• Computational psychiatry as a bridge from neuroscience to clinical applications (2016, methodology): “Finally, these approaches may be fundamentally limited because they reify 46 symptom-based classification, although they could feasibly be used to refine them by subdividing existing classes 1 .”
• Great Expectations: Using Whole-Brain Computational Connectomics for Understanding Neuropsychiatric Disorders (2014, background): “Functional changes have also been found a subtle randomization of functional networks, with decreased small-world properties, lower clustering coefficients and fewer high-degree hubs (Bassett et al., 2012; Liu et al., 2008; Lynall et al., 2010).”
• Definition and description of schizophrenia in the DSM-5. (2013, background): “, biological markers) is less robust (Kapur et al., 2012).”
• Clinical applications of the functional connectome (2013, neutral): “, DN dysregulation) or structure in any given disorder, it does not provide a means for assessing the specificity of findings to the disorder under inquiry (Kapur et al., 2012).”